CoChat

Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma

Open access
Sakurai, Toshiharu, Kudo, Masatoshi · 2013 · Liver Cancer
Cited by 58

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, which is usually associated with a very poor prognosis [1], and is the third leading cause of cancer deaths worldwide. Most HCCs develop in the context of severe liver fibrosis and cirrhosis caused by chronic liver inflammation. Chronic infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) as well as hepatosteatosis, are the major risk factors for both liver cirrhosis and HCCs. In the case of HCV, HCC develops after one or more decades of chronic infection, and an elevated risk of HCC progression is restricted largely to patients with cirrhosis or advanced fibrosis. Thus, the risk of hepatocarcinogenesis depends on background liver factors, of which fibrosis is a major determinant. Development and progression of liver fibrosis are associated with hepatocyte death and a subsequent inflammatory response [2], both of which involve reactive oxygen species (ROS) accumulation in injured hepatocytes. Given that the risk of human HCC recurrence after hepatectomy is positively correlated with protein oxidation in the liver, augmented oxidative stress of liver parenchymal cells may explain the close relationship between liver fibrosis and hepatocarcinogenesis [3]. In this issue, Ramakrishna et al. review possible molecular links between liver fibrosis and HCC [4]. Critical regulators of liver cancer development are inflammation in the context of the NF-κB/STAT3/JNK axis and inflammasome, and also cellular senescence. Like IKKβ, the catalytic subunit of the IκB kinase complex required for NF-κB activation, p38α prevents ROS accumulation and excessive JNK activation, thereby maintaining hepatocyte survival and suppressing liver injury [3,5]. Hepatocyte IKKβ and p38α inhibit hepatocarcinogenesis by suppressing accumulation of ROS and inflammation, whereas JNK activation promotes ROS accumulation, hepatitis, and carcinogenesis [5,6]. p38 is essential for ras-induced senescence, an important tumor-suppressing defense mechanism [7], while JNK suppresses p53-dependent senescence [8]. p38 and JNK antagonistically control senescence and cytoplasmic p16INK4A expression in doxorubicin-treated endothelial progenitor cells [9]. A better understanding of cross-talk between inflammation and cellular senescence is of great importance. Identification of the cellular origin of HCC will help in targeted therapeutics directed towards the most dreadful consequence of chronic inflammation, HCC development. The concept that tumors are maintained by dedicated stem cells, the so-called cancer stem cell hypothesis, has attracted much interest. According to this hypothesis, cancer cannot be viewed as simple monoclonal expansions of functionally equal tumor cells. Instead, only a small minority of tumor cells, the cancer stem cells or tumor-initiating cells, have the ability to maintain the malignant population [10]. Deletion of IKKβ enhances proliferation of tumor-initiated cells and accelerates HCC development. These effects of IKKβ are correlated with increased accumulation of ROS that leads to JNK and STAT3 activation [11]. The positive cross-talk between JNK and stem cell expansion is evident in human HCC studies [12]. Deletion of p38α, which leads to JNK activation, upregulates expression of SOX2 and Gankyrin, which may be involved in cancer stem cell maintenance [3]. The NF-κB/STAT3/JNK signaling pathway in cancer stem cells may be a promising therapeutic target. The molecular etiology of HCC has been extensively studied using transgenic or chemically induced mouse models [13,14]. The chemical procarcinogen diethylnitrosamine (DEN)-induced HCC depends on production of the NF-κB-regulated cytokine IL-6 by resident Kupffer cells [15]. In this case, Kupffer cells are activated by IL-1α released by apoptosing hepatocytes [5]. Interestingly, male mice produce more IL-6 upon DEN administration than females, which accounts for the marked male bias in HCC induction studies. Mice administered thioacetamide for 10 months develop HCCs subsequent to appearance of severe liver fibrosis, thus providing a model that closely mimics the natural history of human HCV-related liver disease [3]. These animal models are critical for finding answers to key questions raised by the authors. Unlike most solid tumors, the incidence and mortality of HCC have increased in the United States and Europe in the past decade. The findings implicating a pivotal signaling pathway in HCC development suggest the potential use for blocking agents and/or modulators for HCC treatment. Therefore, it is important to improve our understanding of the molecular pathogenesis of HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000343851

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 58

Metadata

Authors
Sakurai, T., & Kudo, M.
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2013
Volume
2
Issue
3-4
Pages
365-366
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
OpenAlex
W2045400180
Cited by
58
References
3
FWCI
1.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.